# Aulos Bioscience

> Aulos Bioscience is a Larkspur, California, clinical-stage immuno-oncology company using artificial intelligence to design antibody therapeutics that unlock the anti-cancer power of interleukin-2 (IL-2). Its lead candidate, imneskibart (AU-007) - described as the first AI-designed human monoclonal antibody to enter human clinical trials - redirects IL-2 away from immune-suppressing regulatory T cells and toward immune-activating effector T cells and NK cells, aiming to treat solid tumors such as melanoma and non-small cell lung cancer while avoiding the toxicity that has limited earlier IL-2 therapies.

- **Founded:** 2020
- **Headquarters:** Larkspur, California, United States
- **Founders:** Yanay Ofran (Co-founder & Chief Scientific Officer (founding CEO); CEO/founder of Biolojic Design), Michael Ehlers (Co-founder & Executive Chair (Apple Tree Partners)), Micah Pearlman (Co-founder & Chief Operating Officer)
- **Team size:** ~15 employees
- **Products:** imneskibart (AU-007)
- **Notable:** AU-007 (imneskibart) described as the first AI-designed human monoclonal antibody to enter human clinical trials., FDA cleared the IND application for AU-007 in October 2022., Dosed first U.S. patient in the Phase 1/2 solid-tumor trial in early 2023.

## Products & services

- **imneskibart (AU-007)** — Lead AI-designed human monoclonal antibody targeting IL-2. It binds IL-2 to prevent it from engaging trimeric CD25 receptors on regulatory T cells, while still allowing IL-2 to expand effector T cells and NK cells - biasing the immune system toward tumor attack and away from suppression. In Phase 2 trials for solid tumors including melanoma and non-small cell lung cancer.

## Achievements

- AU-007 (imneskibart) described as the first AI-designed human monoclonal antibody to enter human clinical trials.
- FDA cleared the IND application for AU-007 in October 2022.
- Dosed first U.S. patient in the Phase 1/2 solid-tumor trial in early 2023.
- Raised ~$60M total from Apple Tree Partners ($40M Series A + $20M extension).
- Reported durable anti-tumor responses in 2025 Phase 2 data, including a 100% tumor reduction in one CPI-refractory melanoma patient treated beyond 21 months.

## Latest updates

- **2025-11** — Presented new Phase 2 data for imneskibart (AU-007) at the 40th SITC Annual Meeting, showing durable clinical activity in CPI-refractory melanoma and NSCLC, including tumor reductions of 48%, 58% and 100% in three long-term melanoma patients (data cutoff Sept 29, 2025).
- **2023-08** — Raised $20 million in Series A extension financing from Apple Tree Partners.
- **2023-02** — Dosed first U.S. patient in the Phase 1/2 clinical trial of AU-007 for solid tumors.
- **2022-10** — Announced FDA clearance of the IND application for AU-007.

## Links

- Website: https://aulosbio.com
- LinkedIn: https://www.linkedin.com/company/aulos-bioscience
- Twitter/X: https://twitter.com/aulosbioscience

---

Profile page: https://yespress.io/aulos-bioscience
Published by YesPress — https://yespress.io
Last updated: 2026-07-13